Article
Nicotinamide Ameliorates Disease Phenotypes in a Human iPSC Model of Age-Related Macular Degeneration Graphical Abstract
Authors Janmeet S. Saini, Barbara Corneo, Justine D. Miller, ..., Timothy A. Blenkinsop, Jeffrey H. Stern, Sally Temple
Correspondence sallytemple@neuralsci.org
In Brief Saini et al. show that hiPSC-derived RPE, including ARMS2/HTRA1 homozygotes, from AMD patients exhibit higher complement and inflammatory factors compared to healthy controls. Nicotinamide treatment reduces these and other AMD-related molecules with no observed cytotoxicity. Pursuing nicotinamide’s mechanism of action should reveal new therapeutic approaches for AMD.
Highlights d
Complement and inflammatory factors are upregulated in AMD hiPSC-derived RPE
d
Nicotinamide inhibits AMD biomarkers, including drusen components and VEGFA
d
Nicotinamide suppresses production of complement and inflammatory factors
d
Nicotinamide increases RPE cell survival while targeting aging-associated pathways
Saini et al., 2017, Cell Stem Cell 20, 635–647 May 4, 2017 ª 2017 Elsevier Inc. http://dx.doi.org/10.1016/j.stem.2016.12.015
Data Resources GSE90889